* Availability of ultrasound-guided breast biopsy and, in case of B3 lesions at needle biopsy, the vacuum-assisted excision, or surgical specimens or a clinical follow-up outcome in at least 12 months subsequent to the biopsy.
2. Prospective study part:
* Signed informed consent to participate in the study.
You may not be if
1. Retrospective study part:
* Not availability of ultrasound-guided breast biopsy and, in case of B3 lesions at needle biopsy, the vacuum-assisted excision, or surgical specimens, or a clinical follow-up outcome in at least 12 months subsequent to the biopsy. Age \< 18 or \> 89 years.
2. Prospective study part:
* Not availability of Signed informed consent to participate in the study. Age \< 18 or \> 89 years.
Clareo Health | TRACE4BUS for BI-RADS Classification
